Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies-Reference-Cited by-同舟云学术

Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies

Published:2016-10 Issue:10 Volume:38 Page:2286-2299
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Dirix Luc,Swaisland Helen,Verheul Henk M.W.,Rottey Sylvie,Leunen Karin,Jerusalem Guy,Rolfo Christian,Nielsen Dorte,Molife L. Rhoda,Kristeleit Rebecca,Vos-Geelen Judith de,Mau-Sørensen Morten,Soetekouw Patricia,van Herpen Carla,Fielding Anitra,So Karen,Bannister Wendy,Plummer Ruth

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference35 articles.

1. Trapping of PARP1 and PARP2 by clinical PARP inhibitors;Murai;Cancer Res,2012

2. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin;Evers;Clin Cancer Res,2008

3. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs;Rottenberg;Proc Natl Acad Sci USA,2008

4. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy;Farmer;Nat,2005

5. FDA. Olaparib. 2014. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm427598.htm. Accessed July 8, 2016.

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical implications of the Drug-Drug Interaction in Cancer Patients treated with innovative oncological treatments;Critical Reviews in Oncology/Hematology;2024-08

2. Simultaneously Inhibiting P-gp Efflux and Drug Recrystallization Enhanced the Oral Bioavailability of Nintedanib;Current Pharmaceutical Biotechnology;2023-12

3. Pharmacokinetic boosting of olaparib: A randomised, cross-over study (PROACTIVE-study);European Journal of Cancer;2023-11

4. Hematological Toxicities with PARP Inhibitors in Prostate Cancer: A Systematic Review and Meta-Analysis of Phase II/III Randomized Controlled Trials;Cancers;2023-10-09

5. PARP inhibitors: A review of the pharmacology, pharmacokinetics, and pharmacogenetics;Seminars in Oncology;2023-10